Participated · Series D · Aug 2026

Abcuro develops immunotherapies intended to benefit people with debilitating and progressive rare autoimmune diseases by selectively targeting and depleting highly cytotoxic T cells. Its lead program, ulviprubart, is a monoclonal antibody that targets killer cell lectin like receptor G1 (KLRG1) and is currently being evaluated for the treatment of Inclusion Body Myositis (IBM). The company plans to use proceeds from the Series D to support a new potentially registrational clinical study of ulviprubart in patients with less severe IBM. Abcuro is led by CEO Alex Martin and is based in Newton, MA. Financially, it has just completed a $66M Series D financing led by New Leaf Venture Partners with participation from a broad syndicate of life sciences and strategic investors.

Led · Seed · Aug 2026

Bios Life combines clinical, laboratory, and genetic data to create ongoing "digital twin" models that continuously update an individual's cancer risk rather than relying on episodic scans. The company targets cancer survivors and people with higher genetic risk—groups it says together encompass over 40 million Americans—and highlights that more than 40% of people will get cancer in their lifetime with over 30% diagnosed at stage 3 or 4. Founded by former BioNTech executives and other clinicians and product leaders, the team includes ex-BioNTech and InstaDeep personnel leading strategy, AI, and operations. Bios Life owns commercial rights to the Nucleotide Transformer genomics foundation model developed by BioNTech-InstaDeep and has a multi-year data partnership with Tempus, with integration planned for Ambry Genetics. The company raised a $25 million seed round—their first external financing—and intends to use the resources to develop its technology and launch its U.S. platform in H2 2026, with a waitlist already open. Bios Life delivers care through a virtual clinic model with licensed teams working alongside cancer centers to provide continuous monitoring and tailored follow-up.

Led · Series B · Mar 2026

Ambrosia Biosciences develops orally bioavailable small molecules targeting metabolic G-protein coupled receptors, including GLP-1, GIP and amylin. The company combines structural biology with advanced computational chemistry to design molecules with differentiated pharmacology intended for both standalone therapies and strategic combinations. Its lead program is an oral small molecule GLP-1 candidate that the company intends to advance into a Phase 1 clinical trial. The recent $100 million Series B committed capital is intended to fund Ambrosia through clinical trial initiation and to support continued development of its broader small-molecule pipeline. The company is based in Boulder, Colorado, and announced a board appointment tied to the financing.

Participated · Equity · Dec 2025

Impulse Dynamics builds and commercializes the Optimizer platform, a cardiac contractility modulation (CCM) device designed to improve the quality of life for heart-failure (HF) patients who have limited therapeutic options. Led by CEO Jason Spees, the company focuses on both commercial rollout and continued clinical validation of its technology. More than 12,000 patients have already received CCM therapy across clinical trials and real-world settings, with data demonstrating safety and efficacy for HF patients suffering debilitating symptoms. Current initiatives include the INTEGRA-D multicenter study evaluating the CCM-D HF System and the AIM HIGHer trial. The newly secured capital will be directed toward accelerating commercialization, advancing its future product pipeline, and supporting ongoing clinical trials. The company positions itself as a specialized player tackling unmet needs in the large and growing HF market.

Participated · Equity · Oct 2025

ADC Therapeutics develops and commercializes antibody–drug conjugates (ADCs) targeting difficult-to-treat hematologic malignancies, with its lead product ZYNLONTA already approved in the United States and Europe for adults with relapsed or refractory large B-cell lymphoma after at least two prior systemic therapies. The company is advancing additional studies including the LOTIS-5 and LOTIS-7 trials to expand ZYNLONTA’s label, aiming for full enrollment of 100 patients in LOTIS-7 by H1 2026 and additional data in H2 2025. Management is preparing for a potential relaunch of ZYNLONTA in 2027 and intends to invest in commercial expansion to support that goal. Preliminary Q3 revenues from ZYNLONTA were approximately $15.8 million. Prior to the new financing, cash and cash equivalents totaled $234.7 million as of 30 September 2025, and are expected to rise to about $292.3 million after the transaction. The company’s free cash flow was negative $128 million over the last twelve months, underscoring the importance of fresh capital. Shares have risen roughly 262 % in the past six months, trading near a 52-week high of $4.74.